Table 1 Baseline characteristics in the HIT group and the MICT groupa
Variables | HIT (n = 37) | MICT (n = 41) |
|---|---|---|
Sex n (%) men | 28 (76) | 29 (71) |
Age (years) | 50 ± 12 | 48 ± 14 |
Body Mass Index kg/m2 | 24.8 ± 3.4 | 25.6 ± 3.9 |
In a relationship (married/cohabitant) | 22 (61) | 30 (73) |
Employed | 8 (22) | 9 (22) |
Primary diagnosis n (%) | ||
CM/CAD/Other | 21 (57) / 14 (38) / 2 (5) | 31 (75) / 6 (15) / 4 (10) |
Donor age (years) | 37 ± 14 | 39 ± 14 |
Ischaemic time (min) | 181 ± 77 | 184 ± 82 |
Median (IR) years of HF duration pre HTx | 4.0 (9.1) | 4.5 (8.1) |
Median (IR) days on waitlist | 85 (192) | 71 (167) |
Smoking (n (%) No/Ex-smoker) | 18 (49) / 19 (51) | 21 (51) / 20 (49) |
Biomarkers | ||
Hemoglobin (g/dL) | 11.8 ± 1.8 | 11.7 ± 1.6 |
Creatinine (μmol/L) | 116.1 ± 33.9 | 118.5 ± 28.0 |
eGFR (mL/min/1.73m2) | 65.1 ± 20.9 | 62.7 ± 23.3 |
HbA1c (%) | 5.7 ± 0.9 | 5.6 ± 0.7 |
Medication at inclusion n (%) | ||
Ciclosporine | 24 (65) | 31 (76) |
Tacrolimus | 11 (30) | 10 (24) |
Everolimus | 12 (32) | 13 (32) |
Prednisolone | 37 (100) | 41 (100) |
Mycophenolate | 34 (92) | 36 (88) |
Statin | 36 (97) | 41 (100) |
Beta blocker | 9 (24) | 12 (30) |
Calcium blocker | 8 (22) | 12 (30) |
ACE inhibitor | 0 | 2 (5) |
ARB | 4 (11) | 3 (8) |
Diuretics | 31 (84) | 32 (78) |